KMR-206

Overview

KMR-206 is a PARP7 inhibitor with an IC 50 of 13.7 nM. KMR-206 relieves AHR -mediated transcriptional repression and enhances CYP1A1 expression in the presence of TCDD . KMR-206 induces the STING -dependent IFN-β signaling pathway and increases the levels of STAT1 , pSTAT1 and nuclear PARP7 in cancer cells. KMR-206 reduces the viability of lung adenocarcinoma cells, enhances radiation-induced immunogenic signals, and induces the production of immunogenic signals in glioblastoma cancer stem cells . KMR-206 destabilizes FRA1 to increase IRF1 levels and promotes the IRF3 - CBP / p300 interaction. KMR-206 can be used in studies related to lung adenocarcinoma and glioblastoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Lung Adenocarcinoma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > PARP | Products > Signaling Pathways > STAT | Products > Signaling Pathways > STING

Product Information

• Catalog No.: HY-17663
• CAS No.: 2992741-10-1
• Molecular Formula: C29H23FN6O2
• Molecular Weight: 506.53
• Purity: 98.86%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution
• Availability: In-stock

Source

Original product source